Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. · 2018

Read Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. by Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6048158.txt.

Description

Mehra and co-authors report long-term results for pembrolizumab in head and neck cancer. Their pooled analysis appeared in the British Journal of Cancer. The drug blocks the PD-1 immune checkpoint. It was tested in recurrent or metastatic disease. Treatment options after first-line therapy were limited.

The analysis pooled two trial cohorts with 192 patients. Median follow-up reached nine months in the pooled data. The overall response rate was 18 percent. Most responses lasted at least six months. Some continued beyond thirty months of observation. Survival at twelve months was 38 percent. Severe treatment-related side effects affected 13 percent. No deaths were blamed on treatment side effects. The authors support pembrolizumab for this patient group.

Catalog record

CREATORMehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6048158

Browse the full library · About the Tower of Babel